Victory Capital Management Inc. Acquires 224,190 Shares of SiBone (NASDAQ:SIBN)

Victory Capital Management Inc. boosted its position in SiBone (NASDAQ:SIBN - Free Report) by 55.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 631,568 shares of the company's stock after purchasing an additional 224,190 shares during the quarter. Victory Capital Management Inc. owned about 1.49% of SiBone worth $8,861,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SIBN. Proficio Capital Partners LLC bought a new stake in SiBone in the 4th quarter valued at $155,000. Raymond James Financial Inc. bought a new stake in SiBone in the 4th quarter valued at $1,233,000. American Century Companies Inc. boosted its stake in SiBone by 11.0% in the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares during the period. KLP Kapitalforvaltning AS bought a new stake in SiBone in the 4th quarter valued at $97,000. Finally, EntryPoint Capital LLC bought a new stake in SiBone in the 4th quarter valued at $171,000. 98.11% of the stock is currently owned by institutional investors.

SiBone Price Performance

Shares of NASDAQ:SIBN traded down $0.02 during trading on Monday, reaching $17.23. 8,541 shares of the company traded hands, compared to its average volume of 416,809. The company's 50 day moving average is $18.05 and its two-hundred day moving average is $16.57. The firm has a market capitalization of $734.30 million, a PE ratio of -27.02 and a beta of 0.93. The company has a quick ratio of 7.26, a current ratio of 8.53 and a debt-to-equity ratio of 0.21. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. As a group, sell-side analysts predict that SiBone will post -0.78 earnings per share for the current year.

Insider Buying and Selling at SiBone

In related news, Director Jeffrey W. Dunn sold 3,377 shares of the company's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $19.05, for a total transaction of $64,331.85. Following the completion of the sale, the director directly owned 17,354 shares in the company, valued at $330,593.70. This represents a 16.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Anthony J. Recupero sold 3,310 shares of the company's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $18.27, for a total value of $60,473.70. Following the sale, the insider owned 279,121 shares of the company's stock, valued at approximately $5,099,540.67. This represents a 1.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 101,702 shares of company stock worth $1,866,404 over the last quarter. 3.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on SIBN. Truist Financial boosted their price target on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price target on shares of SiBone in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of SiBone in a research report on Tuesday, May 6th.

SiBone Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.